OPEN END TURBO PUT WARRANT - ASTRAZENECA ADR | Market Closed - Börse Stuttgart 11:56:38 28/06/2024 am IST | ||
| 2.56 EUR | +2.81% |
|
| Current month | -2.66% | ||
| 1 month | +2.81% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 2.56 | +2.81% |
| 27/24/27 | 2.49 | +5.06% |
| 26/24/26 | 2.37 | -2.87% |
| 25/24/25 | 2.44 | -2.40% |
| 24/24/24 | 2.5 | -1.57% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 11:56 am IST
More quotesStatic data
| Product type | Knock-Out sin Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | UBS |
| WKN | UM5KAR |
| ISIN | DE000UM5KAR1 |
| Date issued | 14/05/2024 |
| Strike | 105.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.61 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.72 € |
|---|---|
| Lowest since issue | 2.28 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
156.2
USD
Average target price
174.4
USD
Spread / Average Target
+11.69%
- Stock Market
- Certificates
- Certificat
